Tandem Diabetes Care Announces FDA Designation of Basal-IQ Technology as an Interoperable Automated Glycemic Controller
Tandem Diabetes Care, Inc. (TNDM)
Last tandem diabetes care, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.tandemdiabetes.com
Company Research
Source: Business Wire
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of its Basal-IQ™ technology as an interoperable automated glycemic controller (iAGC). This is the second system to receive iAGC designation by the FDA, following the Company’s clearance of the t:slim X2™ insulin pump with Control-IQ™ technology in December 2019.The FDA has classified three categories for the interoperability of devices as a complete automated insulin dosing (AID) system, which include an alternate controller-enabled insulin pump (ACE pump), an integrated continuous glucose monitor (iCGM) and an iAGC. The t:slim X2 insulin pump was also the first to receive an ACE infusion pump classification in February 2019, and the first insulin pump designated as compatible with iCGM devices in June 2018.“Aligning Basal-IQ technology with Control-IQ technology under the FDA’s new regu
Show less
Read more
Impact Snapshot
Event Time:
TNDM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNDM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNDM alerts
High impacting Tandem Diabetes Care, Inc. news events
Weekly update
A roundup of the hottest topics
TNDM
News
- Insulin Pump Market Valuation to Jump to Reach US$ 25.40 Billion by 2033 | India and China Offering Lucrative Growth Opportunities Says Astute Analytica [Yahoo! Finance]Yahoo! Finance
- Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its price target lowered by analysts at Citigroup Inc. from $57.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Tandem t:slim X2 Insulin Pump Now Compatible with Dexcom G7 CGM in CanadaBusiness Wire
- Tandem Diabetes Care, Inc. (NASDAQ: TNDM) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $45.00 price target on the stock.MarketBeat
- Tandem Diabetes: Recurring Value Erosion, Not Right Point In Cycle To Own [Seeking Alpha]Seeking Alpha
TNDM
Earnings
- 11/6/24 - Beat
TNDM
Sec Filings
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- 11/22/24 - Form 4
- TNDM's page on the SEC website